Two Sigma Securities, LLC Acelrx Pharmaceuticals Inc Transaction History

Two Sigma Securities, LLC

11 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2022 Nov 14, 2022	BUY	$0.2 - $0.35 $5,802 - $10,153	29,011 Added 250.27%	40,603 $8,000
Q2 2022 Aug 15, 2022	SELL	$0.18 - $0.29 $5,638 - $9,083	-31,323 Reduced 72.99%	11,592 $3,000
Q1 2022 May 16, 2022	BUY	$0.28 - $0.61 $12,016 - $26,178	42,915 New	42,915 $12,000
Q4 2021 Feb 14, 2022	SELL	$0.49 - $1.02 $11,511 - $23,962	-23,493 Closed	0 $0
Q3 2021 Nov 15, 2021	BUY	$0.93 - $1.51 $21,848 - $35,474	23,493 New	23,493 $24,000
Q2 2019 Aug 14, 2019	SELL	$2.1 - $3.93 $22,404 - $41,929	-10,669 Closed	0 $0
Q1 2019 May 15, 2019	BUY	$2.35 - $3.83 $25,072 - $40,862	10,669 New	10,669 $37,000
Q2 2018 Aug 14, 2018	SELL	$2.13 - $4.2 $31,666 - $62,441	-14,867 Closed	0 $0
Q1 2018 May 15, 2018	SELL	$1.7 - $2.35 $35,375 - $48,901	-20,809 Reduced 58.33%	14,867 $31,000
Q4 2017 Feb 14, 2018	BUY	$1.75 - $5.5 $32,555 - $102,316	18,603 Added 108.96%	35,676 $72,000
Q3 2017 Nov 14, 2017	BUY	$2.9 - $4.6 $49,511 - $78,535	17,073	17,073 $79,000

Ticker ACRX
Exchange NASDAQ
Sector Healthcare
Industry Drug Manufacturers—Specialty & Generic
Shares Outstandng 7,366,600
Market Cap $8.32M
Description
AcelRx Pharmaceuticals, Inc., a specialty pharmaceutical company, focuses on the development and commercialization of therapies for the treatment of acute pain. Its lead product candidate is DSUVIA and DZUVEO, a 30 mcg sufentanil sublingual tablet for the treatment of moderate-to-severe acute pain. The company develops ZALVISO, a pre-programmed ...

Get notified when there are updates to the investment portfolio of Two Sigma Securities, LLC, based on Form 13F filings with the SEC.

Stay updated on Two Sigma Securities, LLC with notifications on news.